WGS
NASDAQGeneDx Holdings Corp.
Price$88.31-4.03 (-4.36%)
01:30 PM07:00 PM
News · 26 weeks51+13%
2026-03-292026-09-20
Mix2090d
- Other8(40%)
- Insider7(35%)
- SEC Filings3(15%)
- Earnings2(10%)
Latest news
25 items- INSIDERCHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 18,750 shares and sold $1,025,013 worth of shares (10,501 units at $97.61), increasing direct ownership by 8% to 115,476 units (SEC Form 4) (withholding obligation)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares and sold $363,892 worth of shares (3,728 units at $97.61), increasing direct ownership by 8% to 44,945 units (SEC Form 4) (tax withholding)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERDirector Fuchs Thomas converted options into 1,146 shares (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 6,547 shares and sold $310,932 worth of shares (3,692 units at $84.22), increasing direct ownership by 3% to 107,227 units (SEC Form 4) to cover taxes4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Feeley Kevin converted options into 2,462 shares and sold $108,220 worth of shares (1,285 units at $84.22), increasing direct ownership by 3% to 41,476 units (SEC Form 4) to satisfy tax liability4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- PRGeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type CNPC GenomeComplete to identify children who might otherwise remain undiagnosed through broad NPC-specific eligibility criteria, comprehensive genomic testing and expert diagnostic support GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a collaboration with Beren Therapeutics P.B.C. to launch the NPC GenomeComplete Sponsored Testing Program. The program provides no-cost comprehensive genome sequencing for eligible pediatric patients with clinical findings, family history, or biomarker evidence suggestive of Niemann-Pick Disease Type C (NPC), helping address barriers to diagnosis and identify children who are currently und
- INSIDERCHIEF FINANCIAL OFFICER Feeley Kevin converted options into 717 shares and sold $31,188 worth of shares (372 units at $83.84), increasing direct ownership by 0.86% to 40,299 units (SEC Form 4) to cover taxes4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- SECSEC Form 144 filed by GeneDx Holdings Corp.144 - GeneDx Holdings Corp. (0001818331) (Subject)
- PRGeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 HonoreeRecognition highlights GeneDx’s leadership in moving genomic medicine to the forefront of healthcare GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 recognizes 50 individuals and organizations driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901577181/en/ "What makes this recognition so meanin
- PRGeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’sPublished in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis Children experiencing faltering growth saw striking 63% diagnostic yield GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new data published in Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), in collaboration with the clinical genetics team at Seattle Children’s. The study demonstrates that implementing first-tier rapid genome sequencing (rGS) broadly across inpatient pediatri
- SECSEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.SCHEDULE 13G - GeneDx Holdings Corp. (0001818331) (Subject)
- PRGeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and EpilepsyNew offering integrates virtual clinicians to create a scalable channel to increase availability of GeneDx exome testing for eligible children facing specialty-care barriers GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced the launch of a new online offering designed to expand accessibility of exome testing across the U.S. at scale for pediatric patients with global developmental delay (GDD), intellectual disability (ID) or epilepsy. Families can now initiate a genetic test directly from GeneDx.com, providing underserved children and families who face barriers to local specialty care with a faster path to c
- SECAmendment: SEC Form SCHEDULE 13G/A filed by GeneDx Holdings Corp.SCHEDULE 13G/A - GeneDx Holdings Corp. (0001818331) (Subject)
- PRGeneDx to Participate in Upcoming Investor ConferencesGeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: Canaccord Genuity 46th Annual Growth Conference Boston, MA Fireside Chat: Tuesday, August 11 at 11:00 a.m. ET Wells Fargo 21st Annual Healthcare Conference Boston, MA Fireside Chat: Tuesday, September 8 at 2:15 p.m. ET Live and archived webcasts of the presentations will be available on the "Events" section of the GeneDx investor relations website at ir.genedx.com/news-events/events. About GeneDx GeneDx’s (NASDAQ:WGS) mission is to empower everyone to live their healthi
- SECSEC Form 10-Q filed by GeneDx Holdings Corp.10-Q - GeneDx Holdings Corp. (0001818331) (Filer)
- SECGeneDx Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - GeneDx Holdings Corp. (0001818331) (Filer)
- PRGeneDx Reports Second Quarter 2026 Financial ResultsReported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue Reported exome and genome volume growth of 32% year-over-year Reported adjusted gross margin(1) of 70% and adjusted net income(1) of $0.4 million Reiterating full year 2026 revenue guidance of $475 to $490 million with exome and genome volume growth of at least 30% Hosting conference call today at 4:30 p.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the second quarter of 2026. "Our team’s unwavering focus and agility drove a strong second
- SECSEC Form 25-NSE filed by GeneDx Holdings Corp.25-NSE - GeneDx Holdings Corp. (0001818331) (Subject)
- PRGeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the second quarter of 2026 after the market closes on Monday, August 3, 2026. Management will host a conference call that day to discuss second quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx GeneDx’s (NASDAQ:WGS) mission
- INSIDERSEC Form 4 filed by President Gardner Mark A4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERDirector Ryan Jason converted options into 3,576 shares, increasing direct ownership by 30% to 15,480 units (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERDirector Ruch Joshua converted options into 3,576 shares, increasing direct ownership by 12% to 33,299 units (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERDirector Pfenniger Richard C Jr converted options into 3,576 shares, increasing direct ownership by 9% to 45,082 units (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERDirector Meister Keith A. converted options into 3,576 shares, increasing direct ownership by 18% to 23,705 units (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
- INSIDERDirector Leproust Emily M. converted options into 3,576 shares, increasing direct ownership by 17% to 24,852 units (SEC Form 4)4 - GeneDx Holdings Corp. (0001818331) (Issuer)
WGS FAQ
6 questionsWhere does WGS stock trade?
GeneDx Holdings Corp. (WGS) is listed on NASDAQ.What sector and industry is WGS in?
GeneDx Holdings Corp. operates in the Technology sector, Retail: Computer Software & Peripheral Equipment industry.When did GeneDx Holdings Corp. go public?
GeneDx Holdings Corp. (WGS) completed its IPO in 2020.What are analysts saying about WGS?
GeneDx Holdings Corp. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight on 2026-02-09. Recent price targets range from $2100.00 to $4300.00.What companies are similar to WGS?
Notable peers in the same industry include HPE (Hewlett Packard Enterprise Company), SNX (TD SYNNEX Corporation), CDW (CDW Corporation), INGM (Ingram Micro Holding Corporation), CDK (CDK Global Inc.). Compare WGS side-by-side with any of them on Quantisnow.How can I track WGS on Quantisnow?
Quantisnow aggregates GeneDx Holdings Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow WGS to receive live email and push alerts on every new disclosure.